Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Takeda Sees 18.5% Sales Rise after Shire Buy, but Braces for Losses in FY2019
Takeda Pharmaceutical saw its consolidated sales grow 18.5% in FY2018 ended March, with Shire’s three-month revenue added following its £46 billion takeover early this year, but the drug giant is bracing for losses in the next fiscal year as acquisition…
To read the full story
Related Article
- Takeda’s FY2019 Revenue Up 57% on Shire Buy, Underlying Growth at 1.6%
May 14, 2020
- Takeda’s April-Dec. Underlying Sales Sag 1.2% as Hemophilia Meds Falter; Outlook Lifted after Buyout Cost Adjustment
February 5, 2020
- Takeda’s Underlying Revenue Skids 0.2% in 1st Half as Rare Disease Biz Weighs
November 1, 2019
- Takeda Squeezes Projected Losses for FY2019 as Velcade Copy Lags
August 1, 2019
- Takeda Cuts FY2018 Profit Outlook on Shire Takeover
April 26, 2019
- Takeda Sees Flat Sales as Brisk US Revenue Offset by Off-Patent Divestiture
November 1, 2018
- Takeda Delivers Double-Digit Profit Growth as Entyvio Nets 200-Plus Billion Yen
May 15, 2018
BUSINESS
- CSL Behring Japan Names Edward Wright as New Chief
October 2, 2026
- Takeda Welcomes 39 Prospective 2027 Hires in Japan
October 2, 2026
- Nippon Shinyaku Reports 5-Year Efficacy Data for DMD Hopeful
October 2, 2026
- Taiho’s ASTX030 Hits PIII Goal, US Filing Planned
October 2, 2026
- Ono Moves US Venture Capital Arm to Cambridge
October 2, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…